Dicot initiates repeated dosing in its clinical study
Press release: Uppsala, November 14, 2023. The potency drug developer Dicot's phase 1 study is now entering its second and final part. After the previously announced start of recruitment of participants to what is called MAD, the dosing itself is now ready to start, where the participants will receive multiple doses.
Tomorrow morning, the first participants in Dicot's second and final part of its phase 1 clinical trial will be dosed. Initially, participants were given a single dose (called Single Ascending Dose, SAD). Now new participants will receive repeated dosing (Multiple Ascending Dose, MAD).
The MAD part is planned to include around 25 participants who are divided into different dose groups where the dosage gradually increases between the different groups. After dosing, frequent safety checks are carried out where, among other things, blood samples, blood pressure and ECG are taken, which is the standard procedure for this type of first in human studies.
This is a placebo-controlled phase 1 clinical trial with the primary objective to evaluate the safety profile of LIB-01 in humans. The entire study is double-blinded, which means that some participants receive LIB-01 and some receive a placebo, and that neither the participant nor the physician knows which of the two was dosed.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 4,400 shareholders. For more information, please visit www.dicot.se.
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.